Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Evetox is a purified Clostridium botulinum toxin type A formulation developed by Bspharm Korea. It is designed for aesthetic and therapeutic applications, primarily for the temporary improvement of moderate to severe glabellar wrinkles (frown lines), facial contouring (such as masseter reduction/jawline slimming), and the treatment of hyperhidrosis (excessive sweating). The product works by temporarily blocking the release of acetylcholine at the neuromuscular junction, thereby reducing muscle activity and smoothing dynamic wrinkles. It is formulated as a vacuum-dried or lyophilized powder containing human serum albumin and sodium chloride as excipients, requiring reconstitution with sterile saline before intramuscular injection.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on clostridium botulinum toxin type A.